Nippon Shinyaku Co., Ltd. (NPNKF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Nippon Shinyaku Co., Ltd. (NPNKF) with AI Score 61/100 (Hold). Nippon Shinyaku Co. , Ltd. is a Japanese pharmaceutical company focused on manufacturing and selling drugs and functional foods globally. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 18, 2026Nippon Shinyaku Co., Ltd. (NPNKF) Healthcare & Pipeline Overview
Nippon Shinyaku Co., Ltd., founded in 1911, develops and markets pharmaceuticals and functional foods, focusing on urological, hematological, and cardiovascular therapeutic areas. With a presence in Japan, Switzerland, and internationally, the company maintains a diversified product portfolio and a commitment to research and development within the specialty and generic drug market.
Investment Thesis
Nippon Shinyaku presents a stable investment profile with a P/E ratio of 11.74 and a dividend yield of 2.38%. The company's consistent profitability, demonstrated by an 18.0% profit margin and a 67.3% gross margin, supports its financial stability. Growth catalysts include the expansion of its pharmaceutical product line and continued development in functional foods. However, potential risks include regulatory challenges in the pharmaceutical industry and competition from larger generic drug manufacturers. The company's low beta of 0.09 suggests lower volatility compared to the broader market.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $2.16 billion indicates a solid valuation within the specialty and generic drug sector.
- P/E ratio of 11.74 suggests the company may be undervalued compared to its earnings.
- Profit margin of 18.0% demonstrates efficient operations and strong profitability.
- Gross margin of 67.3% reflects a strong ability to control production costs and maintain pricing power.
- Dividend yield of 2.38% provides a steady income stream for investors.
Competitors & Peers
Strengths
- Established presence in specialized therapeutic areas.
- Strong research and development capabilities.
- Diversified product portfolio.
- Consistent profitability and financial stability.
Weaknesses
- Limited geographic reach compared to larger pharmaceutical companies.
- Dependence on key products for revenue generation.
- Exposure to regulatory risks and patent expirations.
- Smaller market capitalization compared to major competitors.
Catalysts
- Potential regulatory approvals for new drug candidates in the pipeline.
- Expansion of existing product lines into new geographic markets.
- Continued investment in research and development of innovative therapies.
- Strategic partnerships and acquisitions to expand product portfolio.
- Growth in the functional foods segment driven by increasing consumer demand.
Risks
- Increasing competition from generic drug manufacturers.
- Regulatory changes and pricing pressures in the pharmaceutical industry.
- Patent expirations on key products.
- Economic downturns and healthcare spending cuts.
- Limited financial disclosure due to OTC listing.
Growth Opportunities
- Expansion of Urological Disease Treatments: Nippon Shinyaku can capitalize on the growing prevalence of urological disorders, such as benign prostatic hyperplasia and overactive bladder, by expanding its product line and geographic reach. The global urology market is projected to reach $48.9 billion by 2027, offering significant growth potential. The company's existing drugs like Zalutia and Eviprostat provide a strong foundation for further development and market penetration.
- Development of Hematologic Malignancy Therapies: With products like Vidaza and Cylocide, Nippon Shinyaku has a foothold in the hematologic malignancy market. The global market for hematologic cancer therapeutics is expected to reach $17.8 billion by 2028. Investing in research and development of novel therapies and expanding indications for existing drugs can drive significant revenue growth.
- Growth in Functional Foods Segment: The increasing consumer focus on health and wellness presents a growth opportunity for Nippon Shinyaku's functional foods segment. The global functional foods market is projected to reach $267.92 billion by 2027. Developing innovative products with scientifically proven health benefits and expanding distribution channels can drive growth in this segment.
- Strategic Partnerships and Acquisitions: Nippon Shinyaku can pursue strategic partnerships and acquisitions to expand its product portfolio, geographic reach, and technological capabilities. Collaborating with other pharmaceutical companies or acquiring smaller biotech firms can provide access to new drug candidates and technologies, accelerating growth and diversification.
- International Expansion: Expanding into new international markets, particularly in Asia and Europe, can drive revenue growth for Nippon Shinyaku. The company can leverage its existing product portfolio and expertise to penetrate these markets, either through direct sales or partnerships with local distributors. Adapting products to meet local regulatory requirements and consumer preferences will be crucial for success.
Opportunities
- Expansion into new international markets.
- Development of novel therapies for unmet medical needs.
- Strategic partnerships and acquisitions.
- Growth in the functional foods segment.
Threats
- Increasing competition from generic drug manufacturers.
- Regulatory changes and pricing pressures.
- Patent expirations on key products.
- Economic downturns and healthcare spending cuts.
Competitive Advantages
- Proprietary pharmaceutical products with patent protection.
- Established brand reputation in specialized therapeutic areas.
- Strong relationships with healthcare providers and distributors.
- Expertise in research and development of innovative therapies.
About NPNKF
Founded in 1911 and headquartered in Kyoto, Japan, Nippon Shinyaku Co., Ltd. has evolved into a global pharmaceutical and functional food manufacturer. The company operates through two primary segments: Pharmaceuticals and Functional Food. Its pharmaceutical division develops, manufactures, and markets drugs for a range of therapeutic areas, including urological diseases, inflammation and allergies, hematologic malignancies, cardiovascular and metabolic diseases, and gastrointestinal disorders. Key products include treatments for urinary disorders, prostatic hypertrophy, prostate cancer, erectile dysfunction, myelodysplastic syndrome, and pulmonary arterial hypertension. The Functional Food segment provides health food ingredients, preservatives, protein preparations, supplements, and spices and condiments. Nippon Shinyaku's geographic reach extends beyond Japan to include Switzerland and other international markets. The company is committed to research and development, focusing on gynecology, otorhinolaryngology, and orthopedics. With 2,213 employees, Nippon Shinyaku balances its established product lines with innovation in specialized therapeutic areas, positioning itself as a key player in the specialty and generic drug market.
What They Do
- Manufactures and sells pharmaceuticals for urological diseases.
- Develops drugs for inflammation and allergies.
- Produces treatments for hematologic malignancies.
- Offers medications for cardiovascular and metabolic diseases.
- Provides drugs for gastrointestinal disorders.
- Manufactures and sells functional foods and supplements.
- Conducts research and development in gynecology, otorhinolaryngology, and orthopedics.
Business Model
- Develops and manufactures proprietary pharmaceutical products.
- Markets and sells pharmaceuticals through its own sales force and distribution network.
- Generates revenue from sales of functional foods and supplements.
- Invests in research and development to create new products and expand indications for existing drugs.
Industry Context
Nippon Shinyaku operates in the global specialty and generic drug market, which is characterized by increasing demand for affordable healthcare solutions. The market is driven by an aging population, rising prevalence of chronic diseases, and the expiration of patents on blockbuster drugs. Competition is intense, with major players focusing on R&D to develop innovative therapies and generic versions of existing drugs. Nippon Shinyaku's focus on specialized therapeutic areas like urology and hematology allows it to carve out a niche in this competitive landscape.
Key Customers
- Hospitals and clinics.
- Pharmacies and drugstores.
- Patients with urological, hematological, and cardiovascular diseases.
- Consumers seeking health and wellness products.
Financials
Chart & Info
Nippon Shinyaku Co., Ltd. (NPNKF) stock price: Price data unavailable
Latest News
No recent news available for NPNKF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NPNKF.
Price Targets
Wall Street price target analysis for NPNKF.
MoonshotScore
What does this score mean?
The MoonshotScore rates NPNKF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Toru Nakai
CEO
Toru Nakai serves as the CEO of Nippon Shinyaku Co., Ltd., overseeing the company's global operations and strategic direction. His background includes extensive experience in the pharmaceutical industry, with a focus on research and development, marketing, and business development. He has held various leadership positions within Nippon Shinyaku, contributing to the company's growth and expansion in specialized therapeutic areas. His expertise spans both the pharmaceutical and functional food segments of the business.
Track Record: Under Toru Nakai's leadership, Nippon Shinyaku has focused on expanding its product portfolio and strengthening its presence in key therapeutic areas such as urology and hematology. He has overseen the launch of several new products and the expansion of the company's international operations. His strategic decisions have contributed to the company's consistent profitability and financial stability.
NPNKF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Nippon Shinyaku Co., Ltd. may not meet the minimum financial or disclosure requirements of the higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial reporting, making it difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries higher risks due to the lack of transparency and regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing due to lack of transparency.
- Lower liquidity can lead to price volatility and difficulty in executing trades.
- OTC stocks are subject to less regulatory oversight, increasing the risk of fraud or mismanagement.
- The OTC Other tier carries a higher risk of delisting or going out of business.
- Information asymmetry can disadvantage investors due to the lack of readily available information.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's growth prospects and potential risks.
- Check for any legal or regulatory issues involving the company.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- The company has been in operation since 1911.
- Nippon Shinyaku has a diverse product portfolio in pharmaceuticals and functional foods.
- The company has a global presence with operations in Japan, Switzerland, and internationally.
- Nippon Shinyaku has a history of profitability and financial stability.
Nippon Shinyaku Co., Ltd. Healthcare Stock: Key Questions Answered
What does Nippon Shinyaku Co., Ltd. do?
Nippon Shinyaku Co., Ltd. is a pharmaceutical company that manufactures and sells drugs and functional foods. It operates through two segments: Pharmaceuticals, focusing on treatments for urological diseases, hematologic malignancies, and cardiovascular issues, and Functional Food, which offers health food ingredients and supplements. The company's business model centers on developing proprietary drugs, marketing them globally, and expanding its functional food offerings to meet consumer demand for health and wellness products.
What do analysts say about NPNKF stock?
AI analysis is pending for NPNKF stock. However, based on available financial data, the company has a market capitalization of $2.16 billion, a P/E ratio of 11.74, and a dividend yield of 2.38%. These metrics suggest a potentially undervalued stock with a steady income stream. Investors should conduct their own due diligence and consider the company's growth prospects, competitive landscape, and potential risks before making any investment decisions.
What are the main risks for NPNKF?
NPNKF faces several risks, including increasing competition from generic drug manufacturers, regulatory changes and pricing pressures in the pharmaceutical industry, and potential patent expirations on key products. As an OTC-listed company, it also faces risks associated with limited financial disclosure and lower liquidity. Economic downturns and healthcare spending cuts could also negatively impact the company's financial performance. Investors should carefully consider these risks before investing in NPNKF.
What are the key factors to evaluate for NPNKF?
Nippon Shinyaku Co., Ltd. (NPNKF) currently holds an AI score of 61/100, indicating moderate score. Key strength: Established presence in specialized therapeutic areas. Primary risk to monitor: Increasing competition from generic drug manufacturers. This is not financial advice.
How frequently does NPNKF data refresh on this page?
NPNKF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven NPNKF's recent stock price performance?
Recent price movement in Nippon Shinyaku Co., Ltd. (NPNKF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Established presence in specialized therapeutic areas. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider NPNKF overvalued or undervalued right now?
Determining whether Nippon Shinyaku Co., Ltd. (NPNKF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying NPNKF?
Before investing in Nippon Shinyaku Co., Ltd. (NPNKF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- OTC data may be less reliable than exchange-listed data.
- AI analysis pending for additional insights.